Manuela Valente Sells 4,241 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,241 shares of the stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.05, for a total transaction of $21,417.05. Following the completion of the sale, the insider owned 210,450 shares of the company’s stock, valued at approximately $1,062,772.50. This trade represents a 1.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 20th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total transaction of $1,976.00.
• On Wednesday, April 8th, Manuela Valente sold 3,824 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $18,546.40.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $5.51 on Thursday. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. The firm has a market cap of $462.23 million, a PE ratio of -10.60 and a beta of 0.96. The business has a 50 day moving average of $5.15 and a 200-day moving average of $4.97. SOPHiA GENETICS SA has a 12-month low of $2.92 and a 12-month high of $6.30.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million.

SOPHiA GENETICS News Roundup

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

Wall Street Analysts Forecast Growth

SOPH has been the topic of a number of research analyst reports. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus price target of $7.50.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after buying an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Archon Capital Management LLC increased its holdings in SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock worth $2,061,000 after acquiring an additional 14,342 shares during the period. Finally, Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth $2,157,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.